CS logo
small CS logo
Ocular Oncology Service, Wills Eye Institute

Philadelphia, Pennsylvania, United States
Cancer treatment center in Philadelphia, Pennsylvania
840 Walnut St #1440, Philadelphia, PA 19107

About Ocular Oncology Service, Wills Eye Institute


  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender

Clinical Trials at Ocular Oncology Service, Wills Eye Institute


During the past decade, Ocular Oncology Service, Wills Eye Institute conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Clinical Trials Sponsors and Collaborators


In terms of collaborators to trials, out of the total clinical trials conducted in "Ocular Oncology Service, Wills Eye Institute" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator and "Allergan" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

Clinical Trials Conditions at Ocular Oncology Service, Wills Eye Institute


According to Clinical.Site data, the most researched conditions in "Ocular Oncology Service, Wills Eye Institute" are "Multiple Sclerosis" (2 trials), "Cystoid Macular Edema" (1 trials), "Macular Edema" (1 trials), "Melanoma" (1 trials) and "Radiation Maculopathy" (1 trials). Many other conditions were trialed in "Ocular Oncology Service, Wills Eye Institute" in a lesser frequency.

Clinical Trials Intervention Types at Ocular Oncology Service, Wills Eye Institute


Most popular intervention types in "Ocular Oncology Service, Wills Eye Institute" are "Drug" (4 trials). Other intervention types were less common.
The name of intervention was led by "Cladribine Tablets" (2 trials), "Bevacizumab" (1 trials), "Ozurdex" (1 trials) and "Sub-Tenon triamcinolone 40mg" (1 trials). Other intervention names were less common.

Clinical Trials Genders at Ocular Oncology Service, Wills Eye Institute


The vast majority of trials in "Ocular Oncology Service, Wills Eye Institute" are 4 trials for "All" genders.

Clinical Trials Status at Ocular Oncology Service, Wills Eye Institute


Currently, there are NaN active trials in "Ocular Oncology Service, Wills Eye Institute". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Ocular Oncology Service, Wills Eye Institute, undefined suspended trials, and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Ocular Oncology Service, Wills Eye Institute, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".